Antonio González Martín, MD, PhD, on Ovarian Cancer: PRIMA/ENGOT-OV26/GOG-3012 Trial of Niraparib
ESMO 2019 CongressAntonio González Martín, MD, PhD, of the Clínica Universidad de Navarra, discusses study findings showing niraparib therapy significantly improved progression-free survival in patients with advanced ovarian cancer across biomarker subgroups (Abstract LBA1).
Related Videos
Mansoor R. Mirza, MD, and Robert L. Coleman, MD, on Integrating Velaparib With Chemotherapy and Maintenance Therapy in Gynecologic Cancers
Mansoor R. Mirza, MD, of Copenhagen University Hospital, and Robert L. Coleman, MD, of The University of Texas MD Anderson Cancer Center, discuss phase III study findings, wh...
Tim Meyer, PhD, and Lorenza Rimassa, MD, on Advanced Hepatocellular Carcinoma: CELESTIAL Trial of Cabozantinib
Tim Meyer, PhD, of the University College London, and Lorenza Rimassa, MD, of Humanitas Research Hospital, Milan, discuss their phase III findings on prognos...
Aleix Prat, MD, PhD, on a HER2-Positive Breast Cancer Biomarker: Results From the PAM50 Trial
Aleix Prat, MD, PhD, of Hospital Clinic de Barcelona, discusses the findings of a meta-analysis showing that the HER2-E subtype may predict pathologic complete response beyon...
Maha H.A. Hussain, MD, on Castration-Resistant Prostate Cancer: Olaparib/Enzalutamide/Abiraterone
Maha H.A. Hussain, MD, of Northwestern University Robert H. Lurie Comprehensive Cancer Center, discusses the phase III PROfound trial results on the efficacy of olaparib in m...
Thomas Powles, MD, PhD, on Metastatic Urothelial Cancer: Durvalumab Plus Targeted Treatments
Thomas Powles, MD, PhD, of Queen Mary University of London, discusses the first study to examine immunotherapy and targeted treatment combinations with a personalized approac...
